In this video, Philip J. Mease, MD, discusses the potential for the development of a T-cell engaging antibody.
“There is interest in a pathogenic T-cell population that has been most studied in axial [spondyloarthritis], but there is anticipation that this will also be a pathogenic T-cell population in psoriatic arthritis,” Mease, director of rheumatology research at Providence Swedish Medical Center in Seattle, said.
The cell therapy approach, using monoclonal antibodies directed toward T lymphocytes with the TRBV9-positive signature, has been previously studied in axial spondyloarthritis and